Glypican 3 antibody drug conjugate - Bristol-Myers Squibb
Latest Information Update: 28 Mar 2020
At a glance
- Originator Bristol-Myers Squibb
- Class Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Glypican 3 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Mar 2020 No recent reports of development identified for phase-I development in Cancer in USA (Parenteral)
- 14 Feb 2017 Phase-I clinical trials in Cancer in USA (Parenteral) before February 2017 (Bristol-Myers Squibb pipeline, February 2017)